SLC5A2 and type 2 diabetes mellitus: Our propensity-matched analysis of more than 1,200 Japanese adults with newly treated T2DM showed that starting an SGLT2 inhibitor conferred no incremental protection against major cardiac or cerebrovascular events, all-cause death, or diabetic complications when compared with first-line biguanide therapy over four years, whereas daily drug cost was almost 50% higher for the SGLT2 regimen.